BACKGROUND: Exacerbations of asthma are often associated with rhinovirus (RV)-induced common colds. During experimental RV-infection in healthy subjects, increased levels of the pro-inflammatory mediator IL-1beta and the anti-inflammatory IL-1 receptor antagonist (IL-1ra) have been found in nasal lavage. OBJECTIVE: We postulated that the balance between nasal pro- and anti-inflammatory mediator expression is disturbed in asthma, resulting in more extensive inflammation following RV-exposure in asthma. METHODS: We determined IL-1ra, IL-1beta, and IL-8 in nasal lavages (days -2, 3, and 6) of non-asthmatics and asthmatics (with and without pre-treatment with the inhaled steroid budesonide) before and after experimental RV16-infection (days 0 and 1). RESULTS: Following RV16-infection, a significant increase in IL-8 was observed in the placebo- and budesonide-treated asthmatics (P=0.033 and 0.037, respectively), whereas IL-1beta only increased in the two asthma groups combined (P=0.035). A small, but significant, increase in IL-1ra was only observed in the budesonide-treated asthmatics (P=0.047). At baseline, IL-1ra levels were significantly higher in the non-asthmatics than in the placebo-treated asthmatics (P=0.017). CONCLUSION: These results demonstrate differences between non-asthmatic and asthmatic subjects in the basal levels of nasal cytokines and their inhibitors, and in the effect of experimental RV-infection on these levels. The results indicate that RV may enhance inflammation more markedly in asthmatics, and suggest that this may in part be explained by lower IL-1ra levels. In addition, the observation that budesonide-treatment may result in higher nasal IL-1ra levels supports the hypothesis that steroids act in part by increasing the endogenous anti-inflammatory screen.
RCT Entities:
BACKGROUND: Exacerbations of asthma are often associated with rhinovirus (RV)-induced common colds. During experimental RV-infection in healthy subjects, increased levels of the pro-inflammatory mediator IL-1beta and the anti-inflammatory IL-1 receptor antagonist (IL-1ra) have been found in nasal lavage. OBJECTIVE: We postulated that the balance between nasal pro- and anti-inflammatory mediator expression is disturbed in asthma, resulting in more extensive inflammation following RV-exposure in asthma. METHODS: We determined IL-1ra, IL-1beta, and IL-8 in nasal lavages (days -2, 3, and 6) of non-asthmatics and asthmatics (with and without pre-treatment with the inhaled steroidbudesonide) before and after experimental RV16-infection (days 0 and 1). RESULTS: Following RV16-infection, a significant increase in IL-8 was observed in the placebo- and budesonide-treated asthmatics (P=0.033 and 0.037, respectively), whereas IL-1beta only increased in the two asthma groups combined (P=0.035). A small, but significant, increase in IL-1ra was only observed in the budesonide-treated asthmatics (P=0.047). At baseline, IL-1ra levels were significantly higher in the non-asthmatics than in the placebo-treated asthmatics (P=0.017). CONCLUSION: These results demonstrate differences between non-asthmatic and asthmatic subjects in the basal levels of nasal cytokines and their inhibitors, and in the effect of experimental RV-infection on these levels. The results indicate that RV may enhance inflammation more markedly in asthmatics, and suggest that this may in part be explained by lower IL-1ra levels. In addition, the observation that budesonide-treatment may result in higher nasal IL-1ra levels supports the hypothesis that steroids act in part by increasing the endogenous anti-inflammatory screen.
Authors: Deepti R Nagarkar; Emily R Bowman; Dina Schneider; Qiong Wang; Jee Shim; Ying Zhao; Marisa J Linn; Christina L McHenry; Babina Gosangi; J Kelley Bentley; Wan C Tsai; Umadevi S Sajjan; Nicholas W Lukacs; Marc B Hershenson Journal: J Immunol Date: 2010-07-19 Impact factor: 5.422
Authors: Deepti R Nagarkar; Julie A Poposki; Michael R Comeau; Assel Biyasheva; Pedro C Avila; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2012-05-26 Impact factor: 10.793
Authors: Mingyuan Han; J Kelley Bentley; Charu Rajput; Jing Lei; Tomoko Ishikawa; Caitlin R Jarman; Julie Lee; Adam M Goldsmith; William T Jackson; Mark J Hoenerhoff; Toby C Lewis; Marc B Hershenson Journal: Mucosal Immunol Date: 2019-05-15 Impact factor: 7.313
Authors: Deepti R Nagarkar; Qiong Wang; Jee Shim; Ying Zhao; Wan C Tsai; Nicholas W Lukacs; Uma Sajjan; Marc B Hershenson Journal: J Immunol Date: 2009-10-28 Impact factor: 5.422
Authors: D M Manthei; E A Schwantes; S K Mathur; A G Guadarrama; E A Kelly; J E Gern; N N Jarjour; L C Denlinger Journal: Clin Exp Allergy Date: 2014-12 Impact factor: 5.018
Authors: Mingyuan Han; Tomoko Ishikawa; Jennifer R Bermick; Charu Rajput; Jing Lei; Adam M Goldsmith; Caitlin R Jarman; Julie Lee; J Kelley Bentley; Marc B Hershenson Journal: Allergy Date: 2020-03-10 Impact factor: 13.146
Authors: Clare A Stokes; Saila Ismail; Emily P Dick; Julie A Bennett; Sebastian L Johnston; Michael R Edwards; Ian Sabroe; Lisa C Parker Journal: J Virol Date: 2011-05-18 Impact factor: 5.103